One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Polymyalgia rheumatica: crafting the future of a simple (but not easy!) clinical syndrome
doi : 10.1136/ard-2023-225192
In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation
doi : 10.1136/ard-2023-224728
Expression quantitative trait loci analysis in rheumatoid arthritis identifies tissue specific variants associated with severity and outcome
doi : 10.1136/ard-2023-224540
Single-cell resolution of longitudinal blood transcriptome profiles in rheumatoid arthritis, systemic lupus erythematosus and healthy control pregnancies
doi : 10.1136/ard-2023-224644
Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis
doi : 10.1136/ard-2023-224014
CD_99 G1 neutrophils modulate osteogenic differentiation of mesenchymal stem cells in the pathological process of ankylosing spondylitis
doi : 10.1136/ard-2023-224107
Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica
doi : 10.1136/ard-2023-224768
Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways
doi : 10.1136/ard-2023-224467
Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial
doi : 10.1136/ard-2023-224489
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren’s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial
doi : 10.1136/ard-2023-224691
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry
doi : 10.1136/ard-2023-224819
OA susceptibility in mice is partially mediated by the gut microbiome, is transferrable via microbiome transplantation and is associated with immunophenotype changes
doi : 10.1136/ard-2023-224907
Validation of a new glucocorticoid-specific Patient-Reported Outcome Questionnaire (the Steroid PRO)
doi : 10.1136/ard-2023-224946
Elderly woman with polyarthritis, heliotrope-like rash, lymphadenopathy and polyneuropathy
doi : 10.1136/ard-2023-224711
Time to address the challenge of difficult to treat psoriatic arthritis: results from an international survey
doi : 10.1136/ard-2023-225087
Prevalence of clinically meaningful antiphospholipid antibodies in patients with systemic lupus erythematosus varies by race and ethnicity
doi : 10.1136/ard-2023-224952
Obinutuzumab in patients with Sjogren’s disease immunised against rituximab
doi : 10.1136/ard-2023-224999
Correspondence on ‘2023 ACR/EULAR antiphospholipid syndrome classification criteria’
doi : 10.1136/ard-2023-225042
Response to: Correspondence on ‘2023 ACR/EULAR antiphospholipid syndrome classification criteria’ by Miro-Mur et al
doi : 10.1136/ard-2023-225054
Correspondence on ‘2023 ACR/EULAR antiphospholipid syndrome classification criteria’
doi : 10.1136/ard-2023-225013
Response to: Correspondence on ‘2023 ACR/EULAR antiphospholipid syndrome classification criteria’ by Tang et al
doi : 10.1136/ard-2023-225026
Correspondence on “ACR/EULAR antiphospholipid syndrome classification criteria�
doi : 10.1136/ard-2023-225067
Response to: Correspondence on ‘ACR/EULAR antiphospholipid syndrome classification criteria’ by Damoiseaux and van Beers
doi : 10.1136/ard-2023-225074
Correction: Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study
Correction: A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis
Correction: Proteomic and genomic profiling of plasma exosomes from patients with ankylosing spondylitis
Correction: Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
